Soliris and Pentamidine isethionate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Soliris (eculizumab) and Pentamidine isethionate (pentamidine isethionate). Common drug interactions include aplastic anaemia among females and acute respiratory failure among males.

The phase IV clinical study analyzes what interactions people have when they take Soliris and Pentamidine isethionate. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Soliris?

Soliris has active ingredients of eculizumab. It is often used in paroxysmal nocturnal hemoglobinuria (pnh). eHealthMe is studying from 58,821 Soliris users. Check the latest studies of Soliris.

What is Pentamidine isethionate?

Pentamidine isethionate has active ingredients of pentamidine isethionate. eHealthMe is studying from 1,967 Pentamidine isethionate users. Check the latest studies of Pentamidine isethionate.



On Jul, 13, 2026

13 people who take Soliris and Pentamidine isethionate together, and have interactions are studied.

Soliris and Pentamidine isethionate drug interactions.

What are the common drug interactions of Soliris and Pentamidine Isethionate, by gender? *:

female:

  1. Aplastic anaemia (blood disorder in which the body's bone marrow doesn't make enough new blood cells)
  2. Decreased appetite
  3. Gastric disorder (disease of stomach)
  4. Helicobacter infection (helicobacter pylori (h. pylori) infects stomach)
  5. Nausea (feeling of having an urge to vomit)
  6. Pancreatic disorder
  7. Pancreatitis (inflammation of pancreas)
  8. Abdominal pain
  9. Caecitis (inflammation of the cecum)
  10. Diarrhoea

male:

  1. Acute respiratory failure
  2. Cholestasis (a condition where bile cannot flow from the liver to the duodenum)
  3. Vomiting
  4. Blood lactate dehydrogenase increased
  5. Haemoglobin decreased
  6. Drug resistance (reduction in effectiveness of a drug)
  7. Haemolysis (breaking open of red blood cells and the release of haemoglobin into the surrounding fluid)
  8. Oropharyngeal pain
  9. Platelet count decreased
  10. Diarrhoea

What are the common drug interactions of Soliris and Pentamidine Isethionate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Cholestasis (a condition where bile cannot flow from the liver to the duodenum)
  2. Diarrhoea
  3. Hepatic enzyme increased
  4. Nausea (feeling of having an urge to vomit)
  5. Pneumonitis (inflammation of the walls of the alveoli in the lungs)
  6. Respiratory distress (difficulty in breathing)
  7. Venoocclusive liver disease (small veins in the liver are obstructed)
  8. Vomiting
  9. Aplastic anaemia (blood disorder in which the body's bone marrow doesn't make enough new blood cells)
  10. Acute respiratory failure

10-19:

  1. Drug ineffective
  2. Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)
  3. Blood lactate dehydrogenase increased
  4. Haemoglobin decreased
  5. Abdominal pain
  6. Caecitis (inflammation of the cecum)
  7. Diarrhoea
  8. Oropharyngeal pain
  9. Platelet count decreased

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Decreased appetite
  2. Gastric disorder (disease of stomach)
  3. Helicobacter infection (helicobacter pylori (h. pylori) infects stomach)
  4. Nausea (feeling of having an urge to vomit)
  5. Pancreatic disorder
  6. Pancreatitis (inflammation of pancreas)

60+:

  1. Blood lactate dehydrogenase increased
  2. Drug resistance (reduction in effectiveness of a drug)
  3. Haemolysis (breaking open of red blood cells and the release of haemoglobin into the surrounding fluid)

What are the existing conditions these people have? *

  1. Paroxysmal Nocturnal Haemoglobinuria (haemoglobin in the urine): 6 people, 46.15%
  2. Cytomegalovirus Infection: 2 people, 15.38%
  3. Sleep Disorder: 1 person, 7.69%
  4. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 7.69%
  5. Haemolytic Uraemic Syndrome (blood clotting disease caused by e. coli infection, birth control pills, pneumonia, medications, and more): 1 person, 7.69%
  6. Blood Glucose Increased: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Soliris and Pentamidine isethionate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Soliris and Pentamidine isethionate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Soliris:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Pentamidine isethionate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Soliris and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Pentamidine isethionate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on eculizumab and pentamidine isethionate (the active ingredients of Soliris and Pentamidine isethionate, respectively), and Soliris and Pentamidine isethionate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: